TITLE

Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation—a preliminary study

AUTHOR(S)
Martin, Juergen; Siegenthaler, Michael P.; Friesewinkel, Ortwin; Fader, Tina; van de Loo, Andreas; Trummer, Georg; Berchtold-Herz, Michael; Beyersdorf, Friedhelm
PUB. DATE
June 2004
SOURCE
European Journal of Cardio-Thoracic Surgery;Jun2004, Vol. 25 Issue 6, p971
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: Elevated pulmonary vascular resistance (PVR) unresponsive to pharmacological intervention is a major limitation in heart transplantation (HTX). The post-operative course of these patients is associated with an increased risk of life-threatening right heart failure. We evaluated the efficiency of an implantable left ventricular assist device (LVAD) to decrease PVR by unloading the left ventricle and to lower the risk of later orthotopic HTX. Methods: Six patients with end-stage heart failure (NYHA class IV) and ’fixed‘ pulmonary hypertension (PVR 5.7±0.7, range 4.4–6.5 Wood units) were analyzed. Despite maximal pharmacological intervention at initial evaluation (oxygen inhalation, nitrates, alprostadil infusion) PVR could not be reduced to under 2.5 Wood units. Four patients received a TCI Heartmate, one patient a Novacor, and one patient a Jarvik 2000. Results: All patients survived the LVAD implantation, four patients could be discharged from hospital. Cardiac index and pulmonary artery pressure values returned to normal during the early post-operative phase. After a mean support time of 191±86 days PVR had fallen to 2.0±1.2 (range 0.8–3.6) Wood units. All patients could be bridged to transplantation, one patient died 3 months after transplant, five patients are still alive after a mean follow-up of 16.2±10.5 months. Conclusions: Mechanical support using an implantable LVAD is a very efficient approach with an acceptable risk to treat severe pulmonary hypertension in end-stage heart failure patients before HTX. Adequate reduction of PVR can be expected within 3–6 months. Subsequent HTX is associated with a good outcome.
ACCESSION #
13115576

 

Related Articles

  • Postoperative Pulmonary Hypertension: Etiology and Treatment of a Dangerous Complication. Hill, Nicholas S.; Roberts, Kari R.; Preston, Ioana R. // Respiratory Care;Jul2009, Vol. 54 Issue 7, p958 

    Postoperative pulmonary hypertension is a challenging and feared complication of many types of surgery, including lung and heart transplantation, pulmonary thromboendarterectomy, congenitalheart-disease repair, and others. The most severe manifestation is acute right heart syndrome,...

  • For Patients: A Second Chance.  // Design News;2/10/92, Vol. 48 Issue 3, p73 

    Focuses on the developments of heart failure problems and concerns in the U.S. Inability of a weakened heart to pump the blood needed to nourish muscles and organs that causes death; Citation of a case of left ventricular assist device (LVAD) transplant; Impact of the LVAD transplant on the...

  • Long term results of heart transplantation in patients with amyloid heart disease Dubrey, S W; Burke, M M; Khaghani, A; Hawkins, P N; Yacoub, M H; Banner, N R // Heart;Feb2001, Vol. 85 Issue 2, p202 

    The article presents a study which examines the long-term outcome of heart transplantation in patients with amyloid heart disease. The study evaluated records of all amyloid heart disease patients who underwent heart transplantation to determine the survival, course of the systemic amyloid...

  • Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Braun, Jan-Peter; Schneider, Martin; Kastrup, Marc; Liu, Jianshi // European Journal of Cardio-Thoracic Surgery;Jul2004, Vol. 26 Issue 1, p228 

    An infant, 2 months old, underwent cardiac surgery because of congenital heart defects and pulmonary hypertension. Surgery was performed in hypothermia and cardiac standstill. On the second day after surgery the infant had to be resuscitated due to a combination of acute left-ventricular...

  • Supportive psychotherapy for patients with heart transplantation or ventricular assist devices Heilmann, Claudia; Kuijpers, Nicola; Beyersdorf, Friedhelm; Berchtold-Herz, Michael; Trummer, Georg; Stroh, Anna Lena; Schlensak, Christian; Fritzsche, Kurt // European Journal of Cardio-Thoracic Surgery;Apr2011, Vol. 39 Issue 4, pe44 

    Abstract: Objective: Both heart transplant (HTX) candidates and patients on ventricular assist device (VAD) support suffer from severe heart failure and have to fear life-threatening complications. For both patient groups, the importance of screening for and treatment of psychosocial problems...

  • Treatment changes coming in heart and lung transplants. LoBuono, Charlotte // Drug Topics;8/22/2005, Vol. 149 Issue 16, pHSE12 

    This article presents the guidelines for the management of heart transplant patients from the International Society for Heart & Lung Transplantation. Organ centers must be provided with clear guidelines to help them update their policies regarding waiting lists and the management of potential...

  • Heart to Heart. Pierce, Alan // Tech Directions;Apr2005, Vol. 64 Issue 9, p11 

    This article features technologies used in conducting a heart transplant in the U.S. Apparently, approximately five million people in the United States today, as of April 2005, suffer from congestive heart failure (CHF), a disease that might simply be described as a broken heart. Treatment for...

  • When lightning strikes twice. Rowan, JoAnn; Feller, Leslie Chess // Good Housekeeping;Oct2004, Vol. 239 Issue 4, p70 

    Relates experience of parents in having daughters born with congestive heart failure. Challenges faced during the heart transplant surgery; Signs and symptoms of mitochondrial myopathy, a genetic heart disorder.

  • Cardiac transplantation following ACORN CorCap device implantation Schroder, Jacob N.; Lima, Brian; Rogers, Joseph G.; Milano, Carmelo A. // European Journal of Cardio-Thoracic Surgery;May2006, Vol. 29 Issue 5, p848 

    Abstract: Passive ventricular restraint devices, such as the ACORN CorCap, have been introduced as a potential therapy for congestive heart failure (CHF). These mesh devices act as a mechanical support for the dilated heart. Due to incorporation of the device to the epicardium, concerns about...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics